Inhibikase Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Virtual Conference

Rhea-AI Summary

Inhibikase Therapeutics, Inc. (NASDAQ: IKT) announced that CEO Milton Werner, Ph.D., will present at the H.C. Wainwright & Co. Global Life Sciences Virtual Conference on March 9, 2021. This online presentation can be accessed in the Investors section of their website starting at 7:00 am ET. The webcast will be available for approximately 90 days post-event. Inhibikase focuses on developing therapeutics for Parkinson's disease, with its lead program IkT-148009 currently in Phase I trials assessing its safety and pharmacokinetics.

ATLANTA, Mar. 2, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced that Milton Werner, Ph.D., Chief Executive Officer of Inhibikase, will present at the H.C. Wainwright & Co. Global Life Sciences Virtual Conference.

The presentation will be available for on-demand viewing under "News & Events" in the Investors section of the Company's website at www.inhibikcase.com, beginning Tuesday, March 9th, 2021 at 7:00 am ET. The webcast will be available for approximately 90 days following the event.

About Inhibikase (www.inhibikase.com)
Inhibikase (NASDAQ: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain. Inhibikase is currently escalating dose in its Phase I, randomized single ascending dose and multiple ascending dose study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

View original content to download multimedia:http://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-present-at-hc-wainwright--co-global-life-sciences-virtual-conference-301238073.html

SOURCE Inhibikase Therapeutics, Inc.

FAQ

When will Inhibikase Therapeutics present at the H.C. Wainwright Global Life Sciences Virtual Conference?

Inhibikase Therapeutics will present on March 9, 2021.

Who is presenting for Inhibikase Therapeutics at the conference?

CEO Milton Werner, Ph.D., will present at the conference.

What is Inhibikase Therapeutics' lead program?

Inhibikase's lead program is IkT-148009, targeting Parkinson's disease.

How long will the Inhibikase presentation be available for viewing?

The presentation will be available for approximately 90 days after March 9, 2021.

What does Inhibikase Therapeutics focus on?

Inhibikase focuses on developing therapeutics for Parkinson's disease and related disorders.